Controversial White House plan to overhaul US science funding faces Senate opposition
Summary:
Bipartisan U.S. Senates proposal seeks to temporarily block controversial science funding reforms, protecting peer review and international research collaboration from political oversight.
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
Summary:
Biogen’s promising tau-targeting Alzheimer’s therapy renewed optimism for the field, while unexpected dose-response results raised critical questions about future treatment strategies.
Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one
Summary:
Takeda has discontinued another experimental celiac disease therapy, leaving its pipeline reliant on a single remaining investigational treatment candidate.
Work ethic becomes a flashpoint as China’s biotech pace quickens
Summary:
China’s rapidly growing biotech sector is fueling debate over whether its relentless work culture is reshaping global competition in drug discovery and development.
FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients
Summary:
The FDA approved the first once-daily triple reuptake inhibitor for ADHD, introducing a novel treatment option for both children and adults.
